Kala Pharmaceuticals (NASDAQ: KALA) — Perfil da empresa, notícias e dados financeiros
Kala Pharmaceuticals develops innovative eye care treatments, focusing on therapies for unmet medical needs in eye conditions.
Kala Pharmaceuticals
Kala Pharmaceuticals (NASDAQ:KALA) specializes in developing innovative eye care treatments, particularly focusing on therapies for diseases with significant unmet medical needs. The company works on a range of projects, from early research to advanced clinical trials, aiming to bring groundbreaking solutions to patients suffering from eye conditions worldwide. Key objectives include advancing its pipeline of drug candidates through rigorous testing, securing regulatory approvals, and ultimately improving patient outcomes. With a strong commitment to eye health, Kala Pharmaceuticals is dedicated to making strides in ophthalmic treatment and care.
Resumo
Operações
Produtos e/ou serviços de Kala Pharmaceuticals
- EYSUVIS, a corticosteroid for the short-term treatment of the signs and symptoms of dry eye disease.
- Pipeline focusing on novel treatments for eye diseases using proprietary mucus-penetrating particle (MPP) technology.
- Research on advanced formulations for challenging ocular conditions, aiming to enhance drug delivery and efficacy.
- Clinical trials aimed at expanding applications of their technology in ocular disease treatment.
- Partnerships for the development and distribution of eye care products and technologies.
equipe executiva do Kala Pharmaceuticals
- Mary ReumuthTreasurer & Secretary
- Avi MinkowitzCEO, CFO & Chairman
- Justin HanesFounder & Chair of the Scientific Advisory Board
- Jill S. SteierExecutive Director of Investor Relations & Corporate Communications
- Vincent KosewskiSenior VP of Manufacturing & Supply Chain Management
- Francis S. MahChief Medical Advisor
- Josiah CraverSenior VP & Corporate Controller
- Carl RennieExecutive Director of Account Management
- Patrick BedellExecutive Director of Trade & Alternate Channels
Principais indicadores financeiros
Resultados divulgados pela Kala Pharmaceuticals, em USD.
- Cap. de mercado
- 3,4 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -10.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -39,2 mi | -27 mi | |
| 0 | -40,4 mi | -38,5 mi | |
| 0 | -39,2 mi | -42,2 mi | |
| 3,9 mi | -81,4 mi | -44,8 mi |